Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Cinqaero“
Suchtreffer
Begriffe & Kennungen
Cinqaero
Eintrag öffnenCinqaero · 4.1 Therapeutic indications · 1
Eintrag öffnenCinqaero · 4.3 Contraindications · 1
Eintrag öffnenCinqaero · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenCinqaero · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenCinqaero · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenCinqaero · 4.5 · No formal clinical interaction studies have been performed with reslizumab. In vitro data indicate that IL-5 a
Eintrag öffnenCinqaero · 4.5 · Reslizumab has not been studied in patients concurrently taking immunosuppressant medicinal products other tha
Eintrag öffnenCinqaero · 4.5 · Reslizumab has not been studied in patients receiving live vaccines. No data are available on the secondary tr
Eintrag öffnenCinqaero · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenCinqaero · 4.8 Undesirable effects · 1
Eintrag öffnenCinqaero · 4.8 · 6 Blood creatine phosphokinase elevations were transient and asymptomatic, and did not lead to treatment disco
Eintrag öffnenCinqaero · 4.8 · Anaphylactic reaction The serious adverse reaction of anaphylactic reaction was reported and considered relate
Eintrag öffnenCinqaero · 4.8 · Blood creatine phosphokinase increased
Eintrag öffnenCinqaero · 4.8 · Description of selected adverse reactions
Eintrag öffnenCinqaero · 4.8 · During controlled clinical studies, the proportion of patients who discontinued due to any adverse reaction wa
Eintrag öffnenCinqaero · 4.8 · Experience in paediatric patients is limited (see section 5.1). The data did not indicate a difference in the
Eintrag öffnenCinqaero · 4.8 · In placebo-controlled clinical studies, 6 out of 1,028 patients (0.6%) receiving 3 mg/kg reslizumab had at lea
Eintrag öffnenCinqaero · 4.8 · Malignancies
Eintrag öffnenCinqaero · 4.8 · Myalgia Myalgia was reported in 0.97% of patients (10 out of 1,028) in the 3 mg/kg reslizumab group of the pla
Eintrag öffnen